Search clinical trials for: MK-8521 175μg

Total 1789 results

Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment
Merck Sharp & Dohme LLC

Completed

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Human Immunodeficiency Virus

Romania, South Africa
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Diabetes Mellitus
Hanmi Pharmaceutical Company Limited

Completed

Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects

Healthy

Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Type II Diabetes Mellitus
University of Chicago

Unknown

Effects of Pregnenolone on Perceived Social Isolation

Perceived Social Isolation

United States
Zhejiang ACEA Pharmaceutical Co. Ltd.

Recruiting

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

AML, Adult

China
IBSA Farmaceutici Italia Srl

Recruiting

Evaluation of Safety and Tolerability of Salvia Haenkei Extract as a Dietary Supplement Ingredient

Aging

Switzerland
Masonic Cancer Center, University of Minnesota
Pfizer

Terminated

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Masonic Cancer Center, University of Minnesota
Pfizer

Completed

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

Neoplasms

United States
Pfizer

Completed

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

Melanoma

United States
Rogers, B.H. Gerald, M.D.
3M

Terminated

Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus

Barrett Esophagus

United States
Pfizer

Completed

Use of 852A in Metastatic Cutaneous Melanoma.

Melanoma | Unresectable Metatstatic Cutaneous Melanoma

Switzerland, Germany, France
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); CONRAD

Completed

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

HIV Infections

United States
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
National Institute on Drug Abuse (NIDA)

Completed

The Study of AZD8529 for Smoking Cessation in Female Smokers

Tobacco Use Disorder

United States
Bayer

Completed

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Bronchiectasis

Italy, Spain, Germany, United Kingdom, France
Xeris Pharmaceuticals

Active, not recruiting

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Hypothyroidism

United States
Merck Sharp & Dohme LLC

Completed

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Human Immunodeficiency Virus (HIV) Infection

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Human Immunodeficiency Virus (HIV) Infections
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

United States, Germany
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

HIV-1 Infection

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

HIV-1 Infection

United States, France, Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Influenza

Belgium, France
Zeria Pharmaceutical

Completed

Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Primary Hypophosphatemic Rickets

Japan
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Anza Therapeutics, Inc.

Terminated

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Masonic Cancer Center, University of Minnesota
Pfizer

Completed

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Metastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric Cancer

Taiwan
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension

3

Subscribe